Microgynon ( DrugBank: - )

---

2 diseases

ID	Disease name (Link within this page)	Number of trials
13	Multiple sclerosis/Neuromyelitis optica	3
51	Scleroderma	1

13. Multiple sclerosis/Neuromyelitis optica

---

Clinical trials : 3,340 /  Drugs : 2,163 - (DrugBank : 383) / Drug target genes : 241 - Drug target pathways : 238

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04086225 (ClinicalTrials.gov)	January 17, 2019	9/9/2019	Effects of Cladribine Tablets on the Pharmacokinetics of Microgynon®	A Randomized, Double-blind, 2-Period, 2-Sequence Crossover Phase I Study With a 1 Month run-in Period to Examine the Effect of Cladribine Tablets on the Pharmacokinetics of a Monophasic Oral Contraceptive Containing Ethinyl Estradiol and Levonorgestrel (Microgynon®) in Pre-Menopausal Women With Relapsing Multiple Sclerosis (RMS).	Relapsing Multiple Sclerosis (RMS)	Drug: Cladribine;Drug: Placebo;Drug: Microgynon®	Merck Healthcare KGaA, Darmstadt Germany, an affiliate of Merck KGaA, Darmstadt, Germany	NULL	Recruiting	18 Years	45 Years	Female	34	Phase 1	Germany;Poland
2	NCT03745144 (ClinicalTrials.gov)	January 17, 2019	14/11/2018	Effects of Cladribine Tablets on the PK of Microgynon®	A Randomized, Double-blind, 2-Period, 2-Sequence Crossover Phase I Study With a 1 Month run-in Period to Examine the Effect of Cladribine Tablets on the PK of a Monophasic Oral Contraceptive Containing Ethinyl Estradiol and Levonorgestrel (Microgynon®) in Pre-Menopausal Women With RMS	Relapsing Multiple Sclerosis (RMS)	Drug: Cladribine;Drug: Placebo;Drug: Microgynon®	Merck KGaA, Darmstadt, Germany	NULL	Completed	18 Years	45 Years	Female	24	Phase 1	Germany;Poland
3	EUCTR2011-006043-30-NL (EUCTR)	27/02/2012	16/02/2012	Study to evaluate the effect of oral BAF312 on a monophasic oral contraceptive in healthy female volunteers	An open-label, multiple-dose, two-treatment period study to evaluate the effect of oral BAF312 on the pharmacokinetices and pharmacodynamics of a monophasic oral contraceptive in healthy female volunteers -	healthy volunteers (Multiple sclerosis is the intended indication for BAF312) ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Product Name: BAF312 0,25 mg tablet Product Code: BAF312 Other descriptive name: BAF312 hemifumarate Product Name: BAF312 1 mg tablet Product Code: BAF312 Other descriptive name: BAF312 hemifumarate Product Name: BAF312 4 mg tablet Product Code: BAF312 Other descriptive name: BAF312 hemifumarate Trade Name: Microgynon Product Name: Microgynon INN or Proposed INN: ETHINYLESTRADIOL Other descriptive name: LEVONORGESTREL	Novartis Pharma Services AG	NULL	Not Recruiting			Female: yes Male: no	24		Netherlands

51. Scleroderma

---

Clinical trials : 525 /  Drugs : 565 - (DrugBank : 148) / Drug target genes : 114 - Drug target pathways : 217

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03675581 (ClinicalTrials.gov)	November 8, 2018	17/9/2018	A Study to Test Whether Nintedanib Influences the Components of Birth-control Pills in Women With Systemic Sclerosis Associated Interstitial Lung Disease (SSc-ILD)	A Phase I Trial to Investigate the Effect of Nintedanib on the Pharmacokinetics of a Combination of Ethinylestradiol and Levonorgestrel in Female Patients With Systemic Sclerosis Associated Interstitial Lung Disease (SSc-ILD)	Scleroderma, Systemic	Drug: Microgynon;Drug: Nintedanib	Boehringer Ingelheim	NULL	Completed	18 Years	N/A	Female	17	Phase 1	Belgium;France;Germany;Netherlands;Portugal;Spain